S&P 500

5.918,25

0,00%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Milestone Pharmaceuticals Inc (MIST)
Milestone Pharmaceuticals Inc (MIST) Notícias

MIST

Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:MIST

1 2 3 4 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
07/01/2025	10:00	GlobeNewswire Inc.	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:MIST	Milestone Pharmaceuticals Inc
25/11/2024	02:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:MIST	Milestone Pharmaceuticals Inc
12/11/2024	18:38	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:MIST	Milestone Pharmaceuticals Inc
12/11/2024	18:36	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:MIST	Milestone Pharmaceuticals Inc
12/11/2024	11:12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MIST	Milestone Pharmaceuticals Inc
12/11/2024	09:02	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
29/08/2024	17:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MIST	Milestone Pharmaceuticals Inc
17/07/2024	17:16	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:MIST	Milestone Pharmaceuticals Inc
16/07/2024	19:06	Edgar (US Regulatory)	Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
15/07/2024	17:41	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:MIST	Milestone Pharmaceuticals Inc
15/07/2024	17:38	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:MIST	Milestone Pharmaceuticals Inc
15/07/2024	17:34	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:MIST	Milestone Pharmaceuticals Inc
22/05/2024	09:00	GlobeNewswire Inc.	Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness	NASDAQ:MIST	Milestone Pharmaceuticals Inc
01/03/2024	18:52	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
29/02/2024	09:00	GlobeNewswire Inc.	Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants	NASDAQ:MIST	Milestone Pharmaceuticals Inc
28/02/2024	18:37	GlobeNewswire Inc.	Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants	NASDAQ:MIST	Milestone Pharmaceuticals Inc
14/02/2024	22:56	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MIST	Milestone Pharmaceuticals Inc
26/12/2023	10:54	Dow Jones News	Milestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDA	NASDAQ:MIST	Milestone Pharmaceuticals Inc
26/12/2023	09:57	Dow Jones News	Milestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File Letter	NASDAQ:MIST	Milestone Pharmaceuticals Inc
21/11/2023	09:00	PR Newswire (US)	Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference	NASDAQ:MIST	Milestone Pharmaceuticals Inc
13/11/2023	08:57	PR Newswire (US)	Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates	NASDAQ:MIST	Milestone Pharmaceuticals Inc
11/11/2023	12:00	PR Newswire (Canada)	Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023	NASDAQ:MIST	Milestone Pharmaceuticals Inc
09/11/2023	18:43	Edgar (US Regulatory)	Form SC 13D - General statement of acquisition of beneficial ownership	NASDAQ:MIST	Milestone Pharmaceuticals Inc
07/11/2023	09:00	PR Newswire (US)	Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR	NASDAQ:MIST	Milestone Pharmaceuticals Inc
24/10/2023	08:00	PR Newswire (US)	Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil	NASDAQ:MIST	Milestone Pharmaceuticals Inc
27/09/2023	08:00	PR Newswire (Canada)	Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023	NASDAQ:MIST	Milestone Pharmaceuticals Inc
05/09/2023	08:00	PR Newswire (US)	Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:MIST	Milestone Pharmaceuticals Inc
10/08/2023	08:35	PR Newswire (US)	Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update	NASDAQ:MIST	Milestone Pharmaceuticals Inc
20/06/2023	08:00	PR Newswire (Canada)	Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet	NASDAQ:MIST	Milestone Pharmaceuticals Inc
09/06/2023	17:23	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:MIST	Milestone Pharmaceuticals Inc